Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology

Overview of attention for article published in Frontiers in Pharmacology, March 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
High Attention Score compared to outputs of the same age and source (85th percentile)

Mentioned by

news: 1 news outlet

twitter: 5 X users

Citations

dimensions_citation: 38 Dimensions

Readers on

mendeley: 58 Mendeley

Summary News X Dimensions citations

So far, Altmetric has seen 7 X posts from 5 X users, with an upper bound of 23,533 followers.

Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer's Precision Medicine and Pharm... - PubMed - NCBI https://t.co/WPAwpIQiLn

18 Apr 2019

Reply Repost Favourite

RT @Thomas_Wilckens: Biomarker-Drug and #LiquidBiopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for #Alzheimer’…

17 Apr 2019

Reply Repost Favourite

Biomarker-Drug and #LiquidBiopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for #Alzheimer’s #PrecisionMedicine and #Pharmacology https://t.co/wvLfwBN0Qw @FrontPharmacol @FrontiersIn https://t.co/xC2Re9kieS

17 Apr 2019

Reply Repost Favourite

Our Alzheimer Precision Medicine Initiative (APMI) paper on Biomarker-Drug and Liquid Biopsy Co-development for targeted therapy is published in Frontiers in Pharmacology. (https://t.co/vZYZo1RoLN) ICM - Institut du Cerveau... https://t.co/X1xm5I8zhn

17 Apr 2019

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 3 additional X posts.